SBI JI Innovation Fund

What is SBI JI Innovation Fund?

SBI JI Innovation Fund is a venture capital firm specializing in investments across various stages of a company's growth, including Series A, Series B, Series C, and Pre-IPO phases. With a strong focus on the life sciences sector, they invest in exceptional VC-backed life science companies. They position themselves as creating life science success stories by supporting companies that are grounded yet ambitious, poised to transform their industries with innovative technologies.

The fund shows a specific interest in diverse areas within life sciences such as rare diseases, gene therapy, and gene editing, exemplified by their investment in LogicBio Therapeutics, Inc., which aims to cure serious, early-onset rare diseases. A member firm of the SBI Group from Japan, SBI JI Innovation Fund is committed to the Israeli life science ecosystem.

They operate locally through their Israeli office and are dedicated to fostering an ecosystem that acts as a bridge between Israel and Asia, leveraging over 1,200 investments globally to fuel growth and innovation. On their website, they highlight their involvement in groundbreaking clinical trials and recent strategic partnerships, such as ImmunoBrain Checkpoint's $5 million US NIA Grant for Alzheimer's Disease research and Advaxis's merger agreement with Biosight.

With such a diverse and strategic approach to investment, SBI JI Innovation Fund is positioning itself as a key player in the life sciences sector, promoting the advancement of technologies that could potentially transform healthcare outcomes on a global scale.